Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two active pharmaceutical ingredients: modafinil and paracetamol (also known as acetaminophen). Modafinil is a wakefulness-promoting agent primarily used to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It acts as a central nervous system stimulant with mechanisms that are not fully understood but are believed to involve modulation of various neurotransmitter systems including dopamine reuptake inhibition. Paracetamol is an analgesic and antipyretic agent widely used for the relief of mild to moderate pain and fever; its mechanism involves inhibition of prostaglandin synthesis in the central nervous system. There is no evidence that this specific combination exists as a marketed fixed-dose product; however, both drugs may be co-administered in clinical practice for their respective indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modafinil + paracetamol.